-
FDA approves Shire’s Cuvitru
LEXINGTON, Mass. — The Food and Drug Administration has approved Shire’s latest treatment Cuvitru (immune globulin subcutaneous (human) 20% solution). The drug is indicated to treat adults and pediatric patients ages two years and older with primary immunodeficiency, a group of more than 300 genetic disorders in which a part of the immune system functions improperly or is missing.APhA EVP and CEO named to board of International Pharmaceutical Federation
WASHINGTON – The American Pharmacists Association is furthering its support of global improvements in patient care through volunteer leadership. The International Pharmaceutical Federation recently elected Thomas Menighan, APhA EVP and CEO, to its board as a FIP Bureau VP.